Retatrutide Side Effects: What Studies Saw | Retatrutide Dr
Which Retatrutide side effects happened most often?
Upset stomach and bowel problems topped the list, chiefly while amounts rose. Phase 2 followed 338 people for up to 48 weeks and used no more than 12 mg [3].
Nausea: At 12 mg, up to 60% felt sick to the stomach; rates were lower at 4 mg and 8 mg. Some cases were mild and others moderate, chiefly during the first step-up weeks.
Diarrhea: Rates were 15–33% and rose with the amount. That range can’t give your own risk.
Vomiting: In the higher groups, rates were 21–26%. The figures don’t say how bad your case might be.
Constipation: Rates were 11–16% across the drug groups. Your health and study amount could change your risk.
Less hunger: About 14% reported a drop in hunger as a problem they noticed. Study staff counted it even though eating less was also an aim of the drug.
Shot area trouble: Up to 8% reported it. Your doctor may call this a shot-site reaction.
Phase 3 TRIUMPH-1 was larger and longer, with 2,339 people followed for 80 weeks at no more than 12 mg [23]. Its rates differed from Phase 2.
Nausea was 42.4%. Diarrhea was 32.0%.
Constipation was 26.1%. Vomiting was 25.3%.
Neither Phase 2 study reported a death. When Phase 3 was reported, it hadn’t found a clear warning for a swollen pancreas or tumors in hormone-making thyroid cells [23].
The Phase 3 report doesn’t prove nobody had either problem or rule out a later warning. Rare and long-term harm still need study.
Which serious Retatrutide harms still need an answer?
Few serious harms appeared in the Phase 2 and Phase 3 reports. The work isn’t finished, and the studies watched the problems below [3][16][23].
Faster heartbeat: In Phase 2, heart rate rose by up to 6.7 beats per minute. The highest rise came near week 24, then fell as the top blood-pressure reading fell too [16].
The third copied hormone may cause the faster beat. TRIUMPH studies are still asking whether that change harms people with time.
Uneven heartbeat: One person in the Phase 2 type 2 diabetes group had this problem. It happened in the 8 mg group of 26 people, giving 3.85% [16].
One case in such a small group can’t show your true risk. Larger studies may tell you whether the risk is real.
Heart muscle effects: Phase 2 lab work on human heart tissue found stronger and faster beats. Tissue in a lab can’t show what your whole body would feel at study amounts.
Swollen pancreas: Similar GLP-1 drugs raise concern about this painful illness, called pancreatitis. The Phase 3 report hadn’t found a clear warning for it [23].
Thyroid tumors: Work in rats and mice raised concern about tumors in hormone-making thyroid cells. The Phase 3 report hadn’t found the same warning in people, which isn’t proof of no risk [23].
Blood sugar in type 2 diabetes: One copied hormone could prompt a sugar release from your liver while you haven’t eaten. The other two help insulin, and Phase 2 found a better usual-blood-sugar reading [4].
A long safety study keeps tracking possible heart harm. You don’t yet have the long-term answer.
What may happen after you stop Retatrutide?
As of mid-2026, no long study had followed people after they stopped Retatrutide. The best clue comes from other drugs, not Retatrutide [19].
In STEP 4, people who stopped semaglutide, a weekly shot, regained 6.9% of body weight; those staying on it lost another 7.9%. In SURMOUNT-4, people stopping tirzepatide, another weekly shot, regained 14.0%, while those staying on it lost another 5.5% [19].
Hunger often returns when these drugs stop. The body may burn less fuel too, moving food intake and weight toward where they began.
With similar drugs, most lost weight returned within 12 months [19]. That can’t prove how much you might regain after Retatrutide.
Longer TRIUMPH follow-up may give a Retatrutide answer. For now, the other drugs offer only a rough clue.
How much lost weight may come back after Retatrutide?
A long Retatrutide stop-study hasn’t reported yet. With similar drugs, most lost weight returned within 12 months [19].
That happened in studies called semaglutide STEP 4 and tirzepatide SURMOUNT-4 [19]. Those drugs aren’t Retatrutide, so the amount may not match.
When the copied hormone effects stop, hunger may return. The drug may quiet the drive to eat without ending that drive for good.
A mouse cancer study found that some immune cells kept attacking tumors after Retatrutide stopped [8]. That finding was about tumors, not weight; the mice still regained weight, and no human study has found the same immune effect.
See the Phase 2 and Phase 3 study results for changes while people stayed on Retatrutide. A stop-study is still needed to answer how much weight returns.